Dr Michael Ciesielski | Assistant Professor of Neurosurgery & Oncology
Roswell Park Cancer Institute | United States

Dr Michael Ciesielski, Assistant Professor of Neurosurgery & Oncology, Roswell Park Cancer Institute

Dr. Michael J. Ciesielski joined the Academic Faculty of Roswell Park Cancer Institute (RPCI) in 2004 after obtaining his Ph.D. in Immunology from the State University of New York at Buffalo. Prior to this, he established the Neuro-Oncology laboratory together with Dr. Robert Fenstermaker in 1995. Dr. Ciesielski is an Assistant Professor of Neurosurgery and Oncology at Roswell Park Cancer Institute and member of the Graduate Faculty of the University at Buffalo School of Medicine and Biomedical Sciences. He has co-authored more than 47 journal articles and numerous abstracts. He is an active member of the Society for Neuro-Oncology and American Association for Cancer Research and is a reviewer for numerous scientific journals. Dr. Ciesielski is a co-inventor of the SurVaxM vaccine technology on which MimiVax was founded. He also holds 10 global patents, nine of which are for the survivin technology. Forging ahead with clinical translation of SurVaxM for glioblastoma, he has completed the phase I clinical trial and has led development of SurVaxM through full enrollment of a multicenter phase 2 trial. In his spare time Dr. Ciesielski can often be found coaching youth little league football for Orchard Park, NY.  

Appearances:



DC Co-conference Day 2 April 4 @ 4:40

Targeting cancer through SurVaxM, a new peptide immunotherapeutic vaccine

  • SurVaxM is a synthetic long peptide (SLP) vaccine with incorporated peptide mimic technology
  • Engineered to trigger a stronger immune response than wild type peptide, through better MHC binding 
  • Completed Phase 1 clinical trial in recurrent glioblastoma
  • Interim phase 2 data and designing a phase 3 trial
  • Exploring other indications and combination therapies

back to speakers